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3. Introduction  
3.1 Historical background 
Few “new” procedures, at least within the cardiac surgical community, have been as 
controversial at introduction as OPCAB. Although the procedure had been used for years in 
certain parts of the world (1), many cardiac surgeons were skeptical to OPCAB, as the 
procedure gained popularity in the 1990s.  
Standard coronary artery bypass operation had become one of the most commonly performed 
surgical procedures in the developed world. Outcome studies had shown the value of bypass 
surgery for improving quantity and quality of life (2-5), and many were reluctant to any 
change of such a successful operation.  
A report from the US showed decreased graft patency when bypass surgery was performed 
on the beating heart (6). OPCAB was technically more demanding than CABG performed 
with cardiopulmonary bypass (CPB) (ONCAB). Advocates of the “new” procedure felt that 
OPCAB might offer benefits (7-9). The operation required less equipment, appeared to be 
cheaper, and the deleterious effects of CPB were eliminated (8). 
The French Nobel laureate Alexis Carrell performed experimental coronary bypass 100 years 
ago as pointed out by J. Scott Rankin (1), but clinical application awaited other medical 
discoveries and inventions (10). Milestones were the development of coronary angiography 
(11), use of heparin to prevent clotting of the blood (12) during performance of vascular 
anastomosis and coagulation of blood exposed to the artificial surfaces of the heart lung 
machine. The heart lung machine was a major invention (13, 14), and in 1953 John Gibbon 
performed an intracardiac repair using a heart lung machine (14). The work of Clarence 
Dennis, John H. Gibbon and Clarence Walton Lillehei helped develop a device that could 
pump and oxygenate blood (14-16).  
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Arteriosclerosis and its complications from the brain, the peripheral vascular system and the 
heart reached epidemic proportions. The Framingham study clarified risk factors and etiology 
(17). Myocardial infarction was a common cause of death in both developed and developing 
countries (18). Surgical treatment of vascular manifestations of arteriosclerosis developed 
after the introduction of contrast angiography. Reconstruction of peripheral vascular system 
became common therapies (19). The challenges from operating on the coronary arteries on 
the beating heart were several. Vessels were small, supplied the muscle which maintained the 
circulation, and moved in a three-dimensional space at 60-100 beats pr minute (20). Many 
considered the idea of performing bypass surgery using standard, vascular surgical 
techniques to these small, moving target as equilibristic (21, 22). When the heart lung 
machine was used, the heart could be fibrillated by hypothermia or electric current (23) or the 
aorta clamped intermittently (24) to stop the motion of the heart, giving the surgeon better 
conditions to perform the bypass grafts. Cardioplegic solutions could be used to arrest and 
protect the myocardium, and potassium induced cardiac arrest became a common technique 
since it resulted in a flaccid, nonmoving heart, creating good conditions for the anastomostic 
work (25). 
The heart lung machine, the oxygenator and the plastic tubing used for the extracorporeal 
circuit (26-28) have been subject to research and technical refinements. Surgical experience, 
selection of patients and monitoring of outcomes  increased the safety of CABG (29). The 
value of CABG surgery was documented in randomized studies (5, 30, 31). The studies 
showed improvement in quality and quantity of life in surgically, compared to medically 
treated patients.  
A fraction of patients died or suffered postoperative complications, including damage to the 
central nervous system. Evaluation of alternative treatments was warranted. 
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Andreas Grüntzigs work on balloon dilatation of arteriosclerotic vessels (32) resulted in a less 
invasive treatment of coronary disease (33). The development of intravascular stents 
improved results of percutanous coronary interventions (PCI), especially in the early 
postprocedural phase (33, 34). CABG surgery continued to offer improved outcomes in spite 
of worsened risk profiles (35), as documented by governmental agencies  (36, 37) and 
professional associations (35). Longer-term studies demonstrated that CABG could offer 
better intermediate survival and less reinterventions than PCI in patients with three-vessel 
coronary disease (38), but its invasiveness made surgery less attractive. PCI continued to 
improve technologically (34) and in the approach to restenosis and thrombosis (39-41). 
The development of less invasive surgery for coronary disease started with the Russian 
surgeon Vasilii I. Kolessov, based on the experimental work by Demikhov, was among the 
first to report a clinical series of CABG (42). Kolessov reported on the elimination of CPB, 
sternotomy and suture (43) and performed a bypass graft using a stapler through a left 
anterior thoracotomy without CPB (44). His work was not acknowledged in the USA or 
Western Europe until later. In the meantime, groups from Argentina (45) and Brazil (46) 
reported good results using OPCAB.  
The interest for OPCAB in North America was renewed by Federico Benetti (47), who 
published results of minimally invasive OPCAB (48-50). Similar results were documented by 
Antonio Calafiore (51).  
The introduction of beating heart surgery led to innovations of stabilizers to facilitate the 
suturing (52, 53), devices for automated anastomosis and intravascular shunts to prevent 
ischemia (54).  
This thesis will attempt to use the early clinical studies from Buffalo to demonstrate how 
OPCAB was introduced clinically in a large US hospital. The results will be discussed in the 
context of later publications. The thesis will then discuss the introduction of two important 
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technological modifications of the OPCAB procedure, the use of a stapling device to 
construct anastomosis between the aorta and saphenous veins and the use of intravascular 
shunt during grafting of the coronary arteries. 
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 3.2 Introduction of new methods in surgery 
The evaluation of surgical methods, techniques and tools follows a different path than 
pharmaceutical interventions (55). When new drugs are introduced in the US market place, 
the Federal Drug Administration (FDA) requires rigorous protocols, while medical devices 
may be approved based on simpler investigations, depending on the danger class they are 
assigned to (56). In Europe CE-marking is used to indicate approval of medical devices.  
Surgical procedures may involve administration of pharmaceuticals, implantation of devices 
and a number of other steps making the evaluation complex. The learning curve and surgeon 
skills have impact on outcomes as well as patient selection and perioperative care. It may 
take years before a procedure is standardized and in the meantime further developments may 
modify outcomes.  
McCulloch et al. described an orderly approach to surgical innovation, dividing it in four 
phases (57): 
1 Idea:  In this phase a small number of operations are performed as a proof of concept.  
2a Development: In this phase the procedure is developed further and outcomes monitored.  
2b Exploration: In this phase more surgeons and procedures are included and outcomes 
explored through databases and registries.  
3 Assessment: In this phase the procedure is evaluated through controlled, preferably 
randomized investigations.  
4 Long-term studies: In this phase late outcomes are compared using surveillance of patients 
entered in registries or randomized studies. 
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Although not every surgical procedure can fit into the scheme, it serves as a framework for 
how surgical innovation and development may be evaluated. Randomized controlled studies 
represent the gold standard when defined therapies are compared, but may not be possible or 
ethical if previous studies have shown large benefits or adverse effects of a certain therapy 
(58). Hepatic resection of metastatic colon cancer is considered highly effective in certain 
cases, but has not been subject to randomized studies (59). Similarly, patients with end-stage 
heart failure have not been entered in randomized studies comparing transplantation to 
medical therapy (60).  
Early cardiac surgical procedures were developed to correct conditions causing death or 
disabilities. Successful outcomes represented great benefits compared to non-operative 
treatment that controlled studies were unjustified. As alternative methods, devices or surgical 
techniques were developed, controlled studies became warranted. Numerous randomized 
studies were performed to determine optimal method of myocardial preservation (61-63). 
Similarly, randomized studies were carried out to determine the optimal valvular prosthesis 
(64, 65). The issue of the learning curve was important when difficult operations like the 
“Senning” was compared to “Arterial switch” for transposition of the great arteries (66).  
Although it was known that CABG effectively relieved angina pectoris (67), three 
randomized studies were designed to determine whether the procedure prolonged survival 
compared to medical therapy and in which specific patient groups (5, 68, 69).  
In the mid 1990’s, CABG was routinely performed using CPB and arrested heart. Results 
from South America indicated that elimination of CPB improved results of coronary 
revascularization (47, 70, 71).  
Since OPCAB was an established modification of coronary revascularization, it was 
considered safe to utilize it clinically. At our center in Buffalo, a few surgeons performed 
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OPCAB while others continued to operate using ONCAB, making it possible to compare the 
two procedures using NY State database. This could be classified as phase 2a and b in the 
scheme outlined above (57). The later phases of the evaluation of the OPCAB procedure 
were continued by the institution in Oslo, with which we already cooperated (72). A 
multicenter, partly blinded and randomized study, the ROOBY-study, was conducted in the 
VA system (73), contributing further knowledge to the question of OPCABs role in coronary 
revascularization. 
Surgical procedures are frequently modified by introduction of new innovative technology, 
designed for patient benefit, making the operation simpler, faster or with fewer 
complications. Randomized studies demonstrate that stapled lower colonic anastomosis 
leaked less frequently than hand-sewn (74). Studies of such technical innovations may be 
simpler than studies comparing complex surgical procedures.  
Use of automatic stapling devices to replace suturing of vascular anastomoses was 
anticipated to revolutionize CABG. Staplers create anastomoses quickly, in a standardized 
fashion and relatively independent of surgeons’ skills.  When staplers were used to create 
anastomoses of saphenous veins to the aorta, the chance of embolization and cerebral stroke 
could potentially be reduced. Investigations described in paper 3 and 4 were designed to 
study patency and embolization from anastomoses performed with stapled or hand-sewn 
aorto-saphenous anastomoses.  
Prevention and management of myocardial ischemia is important in OPCAB. If flow in the 
native vessel is occluded during construction of distal anastomoses, hemodynamic collapse 
may occur due to ischemia.  Flow may be maintained during grafting by insertion of a 
temporary shunt. Both interruption of flow and insertion of shunt had been in use, and 
reversal of ischemia demonstrated with shunting in individual cases (54),  but the potential 
benefit of shunt (prevention of ischemia) or adverse effect (vessel damage) had not been 
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thoroughly evaluated in a prospective, randomized fashion. The study described in Paper 5 
was designed to evaluate the potential benefit of shunt.  
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3.3 Ethical considerations 
The studies from Buffalo (Papers 1 and 2) did not require approval from the Ethics 
Committee, since no patients were identified, and the study used prospectively collected data 
mandated by the state. The surgical procedures utilized in the OPCAB patients were 
thoroughly evaluated before implementation, by study tours, proctoring and review of 
literature. The operations were not considered experimental.  
The studies described in papers 3-5 were prospective, controlled studies and required Ethics 
Committee approvals, which were obtained through submission of detailed protocols.   
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4. Aims of the thesis 
Objectives 
The first objective was to evaluate early outcomes and safety of OPCAB of ONCAB, using 
the public registry developed by New York (NY) State.  
The second objective was to evaluate the potential benefit of two technical modifications of 
OPCAB operations:  
Use of an automated proximal connector device to attach saphenous vein-grafts to the 
ascending aorta. 
 Use of intracoronary shunt during the performance of distal anastomosis with the purpose of 
preventing intraoperative ischemia.  
Specific objectives:  
Investigate the safety of OPCAB by comparing operative outcomes of the procedure to 
outcomes of ONCAB using data from a mandatory, public database. (Papers 1 and 2). 
Critically discuss the results of these studies and compare them to clinical series and 
controlled studies. 
Compare clinical and angiographic outcomes in patients having the proximal  
saphenous vein graft anastomoses performed with connector devices or  
 suture technique. Compare the amount of micro embolization to the 
 brain measured by Transcranial Doppler in patients operated with connector and 
 patients operated with traditional technique. (Papers 3 and 4). 
 
Compare the development of ischemia of the myocardium perfused by the left anterior 
descending coronary artery (LAD) during OPCAB performed with obstructive snaring or 
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with intravascular shunt. Study the effects on anastomotic quality by performing on-table- 
and midterm- angiographic studies (Paper 5).
 18 
5. Material and methods 
 
5.1 Early clinical material assessed with the New York State Database tool  
 
Introduction 
 
Buffalo General Hospital, a University hospital, located in Buffalo, New York, was an 
important provider of cardiac surgery. Before initiation of these studies, CABG was almost 
exclusively performed as ONCAB. OPCAB surgery was introduced in cooperation with 
surgeons from Italy and Brazil. The purpose of the study reported on in Papers 1 and 2 was to 
evaluate safety and clinical outcomes of OPCAB- compared to ONCAB- procedures using 
data from the state registry.  
Hypothesis 
The hypothesis of the studies reported on in Papers 1 and 2 was that OPCAB surgery could 
be performed with similar perioperative mortality and complication rates as ONCAB surgery.  
Clinical material 
All patients (n=2001) undergoing CABG at Buffalo General Hospital between January 1, 
1995 and August 31, 1996 were included in Paper 1. Patients undergoing reoperative CABG 
(n=288) between January 1, 1995 and December 31, 1996 were included in paper 2. Patient 
referral was on individual basis, and each surgeon decided method of operation. Some 
cardiac surgeons performed most operations as OPCAB, while others performed ONCAB. 
During the study period 8.5% of patients where operated with OPCAB. Of reoperative cases, 
36 % of the patients were operated with OPCAB. 
Data collection and statistical analysis 
NY State Department of Health required mandatory data-collection of all cardiac procedures 
in the state (75, 76). The data set included demographic data, surgical risk factors, operative 
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details, complications and death. Nurses and physicians collected data, which was quality 
controlled by data collectors and subject to random, on-site reviews by NY State Department 
of Health. Operative mortality was defined as death within 30 days of the operation or before 
discharge from the hospital. Complications were defined according to stringent and 
documentable criteria. 
Operations performed using CPB were designated as ONCAB, and operations performed 
without CPB as OPCAB regardless of the intention at the beginning of the operation. Each 
patient’s estimated mortality rate was calculated based on the risk factors of the individual. 
Using estimated mortality and observed mortality rates, average risk adjusted mortality was 
calculated. The risk adjusted mortality rate was used to compare institutions, surgeons and 
procedures and was important in the quality assessment of cardiac surgery providers (75). 
Estimated-, observed- and risk adjusted mortalities were calculated for OPCAB and ONCAB 
and compared statistically. Similarly, complication-rates were compared. There was no risk 
adjustment for complications, although high estimated mortality rate also predisposed for 
more frequent complications (75). 
Continuous data were analyzed using T-tests, while categorical data were analyzed by chi-
square. All analyses were performed with SPSS software (SPSS Inc.  Chicago, USA). 
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5.2 Investigation of new tools in OPCAB surgery  
5.2.1 Evaluation of the Symmetry
R
 aortic connector vs. hand-sewn proximal 
anastomosis 
Introduction 
Cerebrovascular accident is a serious complication of coronary surgery. The elimination of 
CPB may reduce the risk (77). Embolization during manipulation of the ascending aorta has 
been thought to be a cause of strokes (78). The Symmetry 
R
 connector, which made it 
unnecessary to clamp the aorta, could potentially reduce the chance of embolization. (79, 80). 
Hypothesis 
The hypothesis for this study was that grafts performed with Symmetry
R
 aortic connector 
would have similar angiographic patency, as hand-sutured grafts, and that embolization to the 
brain, measured by Transcranial Doppler, would be reduced. 
Clinical material 
Twenty-three patients underwent OPCAB, having the proximal anastomosis performed with 
the Symmetry
R
 device, while a control group of 23 patients received hand-sewn proximal 
anastomosis. The study was designed as a prospective randomized investigation, but the pilot 
study raised suspicion of problems with the connector anastomosis. The study was redesigned 
to minimize the number of patients exposed to possible adverse effects. Randomization was 
abandoned and a control group with the same inclusion criteria as the pilot patients was 
included. 
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Angiographic investigations 
At the end of the surgical procedure bypass grafts were studied with on-table angiography. 
The angiographic procedures were repeated after three months.  
Transcranial Doppler studies 
Thirty-two of the participants underwent monitoring with multifrequency Transcranial 
Doppler scanning to count the number of gaseous- and solid- emboli to the brain. 
Statistical analysis 
Continuous data were analyzed with T-tests and Mann-Whitney tests, while categorical data 
were analyzed by chi-square. Analyses were performed with SPSS software (SPSS Inc.  
Chicago, USA). 
5.2.2 Evaluation of the use of intracoronary shunt in OPCAB surgery  
Introduction 
Maintenance of hemodynamic stability is essential during OPCAB. Ischemia is the most 
frequent cause of hemodynamic collapse and conversion to CPB (81). A randomized study 
was designed to investigate whether intracoronary shunts could prevent ischemia during 
grafting of the LAD. Potential damage to the vessel from shunt insertion was investigated by 
on-table- and postoperative- angiography.  
Hypothesis 
The hypothesis of the study was that use of intracoronary shunt would prevent ischemia 
compared to occlusion during grafting of the LAD, and that shunt would not compromise the 
quality of the anastomosis. 
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Clinical material 
Fiftysix patients were randomized to a “shunt group” in which the anastomosis between 
LIMA and LAD was performed with an intra-coronary shunt or to a “no-shunt group” in 
which the LAD was occluded with a proximal snare during grafting. 
 Detection of ischemia 
Tissue Doppler with strain measurements (82) was utilized to detect myocardial ischemia. 
Transesophageal ultrasound (System FiVe
R
 echocardiograph (GE Vingmed Ultrasound, 
Horten, Norway) was used. 
Study of anastomotic quality 
Patients underwent coronary angiography on the operating table after completion of the 
operation and after 3 months.  
Statistical analysis  
Data were analyzed using T-tests for continuous data, chi-square for categorical data and 
logistic regression for further analysis. Analyses were performed with SPSS software (SPSS 
Inc.  Chicago, USA). 
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6. Results 
6.1 Operative outcomes in OPCAB surgery 
Preoperative risks 
Preoperative risk factors were more common in OPCAB than ONCAB resulting in a non-
significantly higher estimated mortality rate in OPCAB patients. The difference was not 
significant. 
Operative procedures 
All ONCAB patients were operated with median sternotomy and normothermic or mild 
hypothermic CPB. In OPCAB patients, a varied surgical approach was utilized. In paper 1, 
54 of 172 patients had minimally invasive thoracotomy (MIDCAB) with single bypass to 
LAD, and 2 patients had lateral thoracotomy. In reoperative cases 16 of the OPCABs were 
MIDCABs.  
Average number of grafts per patient was lower in OPCABs reported in paper 1 (1.4 vs. 3.39 
for ONCAB). This difference was also seen in reoperations (OPCAB 1.2 and ONCAB 2.7). 
Mortality and complications 
Estimated mortality rate was higher and observed mortality lower in OPCAB, giving 
identical risk adjusted mortality in the paper 1 material and lower risk adjusted mortality for 
OPCAB in reoperations. None of the mortality differences were significant. 
Complication rates were non-significantly lower in OPCAB in paper 1; the differences were 
significant when reoperations were reviewed separately. Cardiovascular and other 
complications were reduced. This was confirmed in paper 2, where freedom from 
complications in OPCAB was 91.4% vs. 72.1% in ONCAB (p= 0.0001).      
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6.2. Outcomes of OPCAB surgery performed with new technological tools 
6.2.1 Anastomotic quality and micro-embolization in OPCAB surgery performed with 
the Symmetry
R
 aortic connector  
Risk factors and preoperative status 
There were no differences in preoperative clinical status or in operative risk factors. 
On table angiographic studies 
All LIMA to LAD grafts were patent and the saphenous venous grafts had similar patency 
independent of whether connector or hand-sewn technique was used.  
Postoperative angiographic studies 
All LIMA grafts except one were patent on postoperative angiogram. Of 40 saphenous vein 
grafts in the control group, four were occluded and one stenotic, while of 32 studied 
Symmetry
R
 grafts, 16 were occluded and 8 were stenotic. The differences between groups 
were highly significant. 
Embolization by Trans Cranial Doppler 
Micro-embolization counts by Transcranial Doppler were higher in patients operated with the 
connector compared to hand-sewn anastomosis.  The number of gaseous emboli was 
increased in the Symmetry
R
 group, and there was a non-significant increase in the number of 
solid emboli. 
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6.2.2 Intraoperative ischemia and anastomotic quality in patients undergoing OPCAB 
with or without the use of intracoronary shunt 
Septal ischemia during grafting of LAD 
Patients with occlusion of LAD and retrograde filling through collaterals did not develop 
ischemia. Most patients with antegrade flow in LAD developed ischemia when LAD was 
snared, and there was significant difference in the measurements of myocardial strain in 
shunted and non-shunted patients. Ischemia was reversed in almost all shunted patients, while 
the majority of non-shunted patients remained ischemic until reperfusion. None of the 
patients developed hemodynamic instability during grafting of the LAD. 
Ischemia had no demonstrable effect on postoperative levels of cardiac enzymes, nor could 
clinical adverse effects of the ischemia be demonstrated. 
Anastomotic quality 
There was a trend towards improved anastomotic quality in the shunt-group at on-table 
angiogram, but on postoperative angiography findings were similar. All LIMA to LAD grafts 
were patent, but fifteen patients had new coronary lesions in the native vessel, proximal to the 
anastomosis between LIMA and LAD. The new lesions corresponded to the location of the 
proximal snares, which were applied to occlude the LAD. 
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 7. Discussion 
New surgical treatment modalities are presented with increasing frequency. The scientific 
community and commercial operators bring new procedures and medical devices to the 
market, offering improved outcomes for various disease processes. Health authorities and 
third party payers require evidence of efficacy and safety before approving and allowing 
reimbursement of new treatments and procedures. The authorities, device companies and the 
medical community share responsibility for optimizing safety and minimizing adverse effects 
(55).  Simultaneously, improved therapies should not be unduly delayed. As medical care 
becomes increasingly expensive and complex, it will be more important to prove a 
treatment’s impact on quality of life and cost (83). Manufacturers of medical devices are 
responsible for obtaining FDA- or CE- approval prior to market introduction (56). Well-
designed clinical studies are essential for the determination of outcomes related to new 
procedures and devices. Long- term follow-up and post market surveillance is important for 
the evaluation of new procedures and products as demonstrated in the drug-eluting stent 
controversy (84). 
The controlled, prospective, randomized study represents the “gold standard” for comparison 
of competing therapies, although even such studies may be biased (85). After introduction of 
a new method or a device, it may be unrealistic to conduct randomized studies, since data 
needed for planning may be unavailable, and the new treatment may not have been 
adequately defined. Observational studies may reveal more variable results than randomized 
studies (86), but are of value when prospective randomized study may be difficult or even 
unethical (87, 88).  
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At the initiation of OPCAB in Buffalo outcome data for the procedure was largely 
unavailable.  The NY-State registry made it possible to compare perioperative outcomes of 
OPCAB and ONCAB (36, 37).  
In this early phase it was important to establish whether OPCAB was as safe perioperatively 
as the ONCAB technique. There was no assessment of outcomes beyond 30 days or after 
discharge from the hospital. 
These studies demonstrated that patients operated with OPCAB, had a non-significantly 
elevated risk profile, and similar risk adjusted mortality as ONCAB. Complication rates were 
lower in OPCAB reoperations. It was concluded that OPCAB had similar operative safety 
profile as ONCAB, and that avoidance of CPB might reduce complications. An analysis of a 
much larger dataset from the NY State Department of Health, which included almost 50 000 
patients, confirmed lower mortality and complication rates for OPCAB (89).  
There were serious limitations to our early study. Assignment to treatment groups was biased 
and determined by the operating surgeon. NY State data has shown that the surgeon is an 
important risk factor (90), not taken into account in our study. The rate of OPCAB use varied, 
and surgeons with better skills may preferentially have performed one type of surgery. 
“Intention to treat” methodology was not used to establish the groups. Patients. whose 
operation started as OPCAB and were converted to ONCAB, were included in the ONCAB 
group.  Patients prepared for ONCAB who intraoperatively had contraindications to CPB and 
operated with OPCAB, were included in the OPCAB group. Patients converted to ONCAB 
were known to have unfavorable outcomes (81), which could bias results since complications 
or death would be reported in the ONCAB group. Similarly, conversion from ONCAB to 
OPCAB could improve the results of ONCAB by removing high-risk patients from that 
group.   
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The lack of intermediate- and long-term follow up was another limitation of these studies, as 
was the lack of postoperative angiography. A lower number of grafts combined with 
decreased patency could cause earlier return of ischemia and need for reinterventions. This 
was confirmed in the publication from NY State Dept. of Health (89), which demonstrated 
increased reintervention rates in OPCAB. A study from Emory University with more than 12 
000 patients demonstrated lower operative mortality and complication rates in OPCAB (91), 
and similar 10-year survival.  
In spite of the limitations, the studies from Buffalo had importance, being among the first to 
evaluate OPCAB, utilizing a mandatory database. Other studies have shown improved 
operative results, especially in high risk patients (46), (92).  
The group at Rikshospitalet in Oslo, with which our team from Buffalo kept close contact, 
designed a randomized study, comparing OPCAB and ONCAB. Outcomes, including graft 
patency, were similar (72, 93). In contrast, another randomized study showed benefits of 
OPCAB, both perioperatively and at midterm (94). Similarly, a large meta-analysis 
demonstrated perioperative benefits of OPCAB on mortality, complication rates and resource 
use (95). The Belgian surgeon P. Sergeant improved outcomes by changing and re-
engineering his department to OPCAB (96). The perioperative benefits of OPCAB were 
limited to high-risk patients in our studies (97, 98), as have been demonstrated by others 
(92,99).  It may be difficult to design randomized studies for such groups of patients (100). 
The question of whether OPCAB would offer benefits to the average patient requiring 
coronary surgery, needed to be answered by a multicenter, controlled study. 
  
The ROOBY study was designed to evaluate in a randomized partly blinded study important 
safety and efficacy issues related to CABG with or without CPB. Operative mortality, 
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complication rates, graft patency and long term survival were included in this carefully 
powered study, conducted in Veterans Administration hospitals (73). The ROOBY study 
demonstrated worse composite outcomes and lower patency rates of vein grafts in the 
OPCAB group (101). It was argued that the surgeons participating in the study did not have 
adequate exposure to OPCAB (102), but the ROOBY investigators had demonstrated that 
outcomes were independent of  surgeon volume (101). In our experience intraoperative graft 
patency verification is important in OPCAB since 3- 5% of grafts may need revision (103),  
(104). Graft verification does not appear to have been required in the ROOBY study, and this 
may have affected graft patency.  
The role of CPB in coronary surgery remains controversial. Several randomized studies 
including the just cited ROOBY study (93, 101), indicated that OPCAB did not provide any 
benefit compared to ONCAB, while observational studies indicated significant benefits of 
OPCAB especially in high-risk patients (97, 105, 106). One reason may be that the 
randomized studies usually did not include high- risk cases (107). 
 OPCAB has been technically more challenging than ONCAB due to the need for 
hemodynamic stability, stabilization (108) and positioning (109) of the heart during grafting. 
As technological solutions became available, OPCAB became more reproducible. The 
Symmetry
R 
device was designed to decrease embolization and stroke rates, since clamping of 
the aorta became unnecessary during construction of proximal anastomoses. Although initial 
results were promising (79, 80), case reports showed early occlusion in the connector (110). 
We designed a randomized study of risks and benefits of the connector, but found more 
occlusions of vein grafts in the pilot group and redesigned the study.  
The device was used in 23 patients, a sequential group of 23 OPCAB had the proximal 
anastomoses performed by suturing and partial aortic clamping.  
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Vein grafts attached to the aorta with Symmetry
R
 connectors had a high rate of occlusion and 
stenosis (111). The obstructive process seemed to originate in the connector (112, 113). Other 
investigators confirmed the findings (114, 115), while Japanese patients fared better (116). 
Some received anti-thrombotic therapy in addition to aspirin, in contrast to the patients in our 
study. Ethnic factors influence the tendency to arterial thrombosis and thrombocyte reactivity 
(117, 118).  This may have played a role (119) as may have endothelial damage (120). The 
construction of the Symmetry
R
 device left metal surfaces exposed to blood, giving potential 
for thrombogenicity and intimal hyperplasia (121).  
The use of a differently constructed connector resulted in better patency (122). That device 
did not expose metal components to blood, and clopidogrel was administered after surgery 
possibly improving the results (123).  
Previous investigations had shown reduction in the number of emboli during construction of 
proximal anastomoses with Symmetry
R
 connectors (124). The use of ONCAB as control was 
not optimal since ONCAB produced higher embolic counts than OPCAB (125). The 
hypothesis that use of the Symmetry
R
 connector decreased embolic counts (124) was not 
supported by our study (126). On the contrary, patients operated with connector had more 
gaseous- and a trend towards more solid- emboli than patients with hand-sewn anastomoses. 
The importance of emboli during heart surgery has been documented (127). The amount of 
gaseous emboli in the Symmetry
R
 group was surprising, but may have been due to a Venturi 
effect (128).   
Prior to these
 
studies, Symmetry
R
 had been used extensively. A small study like ours, which 
included serial graft angiography contributed significantly to the market withdrawal of a 
dangerous device. The study, in which 46 patients were included and only 23 received the 
connector, demonstrated the value of carefully planned clinical- and angiographic- studies for 
introduction of cardiovascular technology.  
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Patients with critical coronary artery disease are prone to develop myocardial ischemia 
during OPCAB. The practice of occluding native vessels during anastomotic construction 
may cause hemodynamic collapse, necessitating conversion to CPB (129, 130). Insertion of 
an intracoronary shunt during grafting may prevent ischemia, although it has been questioned 
whether the small lumen have adequate blood flow (131).  We demonstrated that ischemia 
was prevented in most patients with antegrade flow in the LAD, while most patients operated 
without shunt were ischemic. Patients with occlusion and retrograde filling of LAD did not 
develop ischemia, since blood was supplied from collaterals.  Relief of ischemia in shunted 
patients was not dependent on shunt-size.Shunts smaller than 1.5 mm were not used (131). 
Although no evidence of hemodynamic compromise or leak of cardiac enzymes was seen in 
the study patients who did not get shunt, ischemia impairs ventricular function (132)  and 
may cause hemodynamic collapse reversible by shunt (54).  
Endothelial damage and development of coronary lesions have been considered a possible 
complication of shunt use (133, 134). Occlusive snaring of arteries results in vessel damage 
in animal models (135) and lower angiographic patency rates (136). Patency rates in this 
study were similar or improved when shunts was used. On angiograms performed after three 
months 15 vessels had obstructive lesions, proximal to the anastomosis, corresponding to the 
occlusive snare. Similar changes were not seen distal to the anastomosis, indicating that the 
use of shunts did not cause permanent damage to coronary arteries.  
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8. Conclusion 
1) Clinical studies using a public database indicated that OPCAB was as safe as ONCAB and 
demonstrated a reduced rate of complications in high-risk patients. Although the 
methodology used had significant limitations, later studies supported the finding that OPCAB 
can be performed with similar safety as ONCAB. However, many of these studies were 
retrospective and not well controlled. Randomized studies have not shown the same benefits 
as those seen in observational-, registry based-, and meta-analytical investigations.  
Regarding the applicability of OPCAB to relatively lower risk patients, the ROOBY study 
has raised significant concerns about whether OPCAB can be recommended as a primary 
technique for most surgeons (101). The issue of whether the surgeons who participated in 
ROOBY had enough OPCAB experience was raised (102), but the authors studied this issue 
carefully and did not demonstrate any outcome difference between surgeons with varying 
OPCAB experience (101). Glance et al. used material from NY-State Database and found no 
volume effect on OPCAB results (137). Based on the study from Oslo (93) and the well-
designed and much larger ROOBY-study, we conclude that OPCAB should not be 
recommended for general use, especially for low risk patients. High-risk patients seem to 
benefit from OPCAB in centers experienced with the procedure (107), corresponding to the 
findings from our early clinical studies. 
2) Use of the proximal connector device, Symmetry
R
, resulted in unacceptable patency of 
vein grafts attached to the aorta during OPCAB. In contrast to what was expected, 
microembolization increased with use of the device. The device has been removed from the 
market. 
3) Intracoronary shunts prevented ischemia during grafting of the antegradely perfused LAD 
during OPCAB. Anastomotic quality was independent of shunt use. On the basis of this 
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study, a recommendation could be given for using intravascular shunt during construction of 
coronary anastomosis in OPCAB procedures.  
 
We have demonstrated that investigations using clinical registries may be valuable during the 
introductory phase of new surgical procedures. The limitations of such studies are many, and 
randomized clinical trials are essential when outcomes of different surgical procedures are 
compared. Introduction of new devices and tools in surgical procedures must undergo 
thorough evaluation under controlled circumstances before being recommended  for routine 
use.  
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9. Future Prospects 
OPCAB and ONCAB are used globally to treat patients with coronary disease. Utilization of 
the procedures varies between countries, regions, institutions and surgeons. In the US, 
OPCAB penetration is about 20% of surgical volume, while Japanese surgeons perform 60 % 
of revascularizations as OPCAB. In Scandinavia the procedure is used in less than 10%.  
Elimination of CPB makes OPCAB less invasive than ONCAB, but the magnitude of the 
procedure is still significant, and as we have demonstrated in this thesis, the elimination of 
CPB does come with additional risks. 
The further minimization of coronary revascularization may require endoscopic or robotic 
approaches (138, 139) and use of automated connectors (140) or semi-automated sutures 
(141). Although such technologies are available and have been used in relatively small series, 
the methods have not been subject to large scale controlled studies. Robotic coronary surgery 
is s technically difficult and in little use (142). The outcomes from connector use are variable 
at best. Reliable connectors with proven intermediate and long-term patency could potentially 
revolutionize CABG by making totally endoscopic procedures simpler (143).  
Performing CABG thoracoscopically without CPB, is still exceedingly difficult. The fact that 
certain individuals may be able to perform such procedures, does not mean that they should 
be promoted for general use.  
Reducing invasiveness remains a goal in coronary surgery, and ideally large incisions and use 
of CPB should be eliminated. Attempts to realize this goal should not compromize the main 
purpose of coronary surgery, to prolong and improve quality of life. Well-planned and non-
biased investigations must be important parts of the realization of our clinical and 
technological goals. 
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